
The Library
Ribosome biogenesis serves as a therapeutic target for treating endometriosis and the associated complications
Tools
Chang, Cherry Yin-Yi, Chiang, An-Jen, Yan, Man-Ju, Lai, Ming-Tsung, Su, Yun-Yi, Huang, Hsin-Yi, Chang, Chan-Yu, Li, Ya-Hui, Li, Pei-Fen, Chen, Chih-Mei, Hwang, Tritium, Hogg, Chloe, Greaves, Erin and Sheu, Jim Jinn-Chyuan (2022) Ribosome biogenesis serves as a therapeutic target for treating endometriosis and the associated complications. Biomedicines, 10 (1). e185. doi:10.3390/biomedicines10010185 ISSN 2227-9059.
|
PDF
WRAP-Ribosome-biogenesis-serves-therapeutic-target-treating-endometriosis-associated-complications-Greaves-2022.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (3375Kb) | Preview |
Official URL: https://doi.org/10.3390/biomedicines10010185
Abstract
Ribosome biogenesis is a cellular process critical for protein homeostasis during cell growth and multiplication. Our previous study confirmed up-regulation of ribosome biogenesis during endometriosis progression and malignant transition, thus anti-ribosome biogenesis may be effective for treating endometriosis and the associated complications. A mouse model with human endometriosis features was established and treated with three different drugs that can block ribosome biogenesis, including inhibitors against mTOR/PI3K (GSK2126458) and RNA polymerase I (CX5461 and BMH21). The average lesion numbers and disease frequencies were significantly reduced in treated mice as compared to controls treated with vehicle. Flow cytometry analyses confirmed the reduction of small peritoneal macrophage and neutrophil populations with increased large versus small macrophage ratios, suggesting inflammation suppression by drug treatments. Lesions in treated mice also showed lower nerve fiber density which can support the finding of pain-relief by behavioral studies. Our study therefore suggested ribosome biogenesis as a potential therapeutic target for treating endometriosis.
Item Type: | Journal Article | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subjects: | Q Science > QH Natural history Q Science > QP Physiology R Medicine > RB Pathology R Medicine > RG Gynecology and obstetrics |
||||||||||||||||||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||||||||||||||||||||
SWORD Depositor: | Library Publications Router | ||||||||||||||||||||||||
Library of Congress Subject Headings (LCSH): | Endometriosis , Endometriosis -- Treatment , Ribosomes , RNA polymerases , Inflammation , Homeostasis | ||||||||||||||||||||||||
Journal or Publication Title: | Biomedicines | ||||||||||||||||||||||||
Publisher: | MDPI | ||||||||||||||||||||||||
ISSN: | 2227-9059 | ||||||||||||||||||||||||
Official Date: | 17 January 2022 | ||||||||||||||||||||||||
Dates: |
|
||||||||||||||||||||||||
Volume: | 10 | ||||||||||||||||||||||||
Number: | 1 | ||||||||||||||||||||||||
Article Number: | e185 | ||||||||||||||||||||||||
DOI: | 10.3390/biomedicines10010185 | ||||||||||||||||||||||||
Status: | Peer Reviewed | ||||||||||||||||||||||||
Publication Status: | Published | ||||||||||||||||||||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||||||||||||||||||||
Date of first compliant deposit: | 23 February 2022 | ||||||||||||||||||||||||
Date of first compliant Open Access: | 24 February 2022 | ||||||||||||||||||||||||
RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year